Moolenaar F - Search Results

1

Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Haverdings RG, Haas M, Navis GJ, van Loenen-Weemaes AM, Meijer DK, de Zeeuw D, Moolenaar F. Haverdings RG, et al. Among authors: moolenaar f. Br J Pharmacol. 2003 Feb;138(4):531. doi: 10.1038/sj.bjp.0705183. Br J Pharmacol. 2003. PMID: 12622114 Free PMC article. No abstract available.

2

Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Haverdings RF, Haas M, Navis G, Van Loenen-Weemaes AM, Meijer DK, De Zeeuw D, Moolenaar F. Haverdings RF, et al. Among authors: moolenaar f. Br J Pharmacol. 2002 Aug;136(8):1107-16. doi: 10.1038/sj.bjp.0704814. Br J Pharmacol. 2002. Retraction in: Br J Pharmacol. 2003 Feb;138(4):531. doi: 10.1038/sj.bjp.0705183. PMID: 12163343 Free PMC article. Retracted.

3

Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.

Kok RJ, Haverdings RF, Grijpstra F, Koiter J, Moolenaar F, de Zeeuw D, Meijer DK. Kok RJ, et al. Among authors: moolenaar f. J Pharmacol Exp Ther. 2002 Jun;301(3):1139-43. doi: 10.1124/jpet.301.3.1139. J Pharmacol Exp Ther. 2002. PMID: 12023548

4

Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.

Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, de Zeeuw D, Meijer DK. Kok RJ, et al. Among authors: moolenaar f. J Pharmacol Exp Ther. 1999 Jan;288(1):281-5. J Pharmacol Exp Ther. 1999. PMID: 9862782

5

Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate.

Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK, Moolenaar F. Prakash J, et al. Among authors: moolenaar f. J Control Release. 2005 Jan 3;101(1-3):350-1. J Control Release. 2005. PMID: 15765569 No abstract available.

6

Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat.

Haas M, Moolenaar F, Meijer DK, de Jong PE, de Zeeuw D. Haas M, et al. Among authors: moolenaar f. Clin Sci (Lond). 1998 Nov;95(5):603-9. doi: 10.1042/cs0950603. Clin Sci (Lond). 1998. PMID: 9791047

7

Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.

Haas M, de Boer E, de Jong PE, Moolenaar F, Meijer DK, de Zeeuw D. Haas M, et al. Among authors: moolenaar f. Clin Sci (Lond). 2003 Jul;105(1):51-7. doi: 10.1042/CS20020205. Clin Sci (Lond). 2003. PMID: 12636872

8

Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.

Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Prakash J, et al. Among authors: moolenaar f. Drug Metab Dispos. 2005 May;33(5):683-8. doi: 10.1124/dmd.104.002808. Epub 2005 Jan 26. Drug Metab Dispos. 2005. PMID: 15673598

9

Low-molecular-weight proteins as carriers for renal drug targeting.

Franssen EJ, Moolenaar F, de Zeeuw D, Meijer DK. Franssen EJ, et al. Among authors: moolenaar f. Contrib Nephrol. 1993;101:99-103. Contrib Nephrol. 1993. PMID: 8467694 No abstract available.

10

Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo.

Haas M, Kluppel AC, Wartna ES, Moolenaar F, Meijer DK, de Jong PE, de Zeeuw D. Haas M, et al. Among authors: moolenaar f. Kidney Int. 1997 Dec;52(6):1693-9. doi: 10.1038/ki.1997.504. Kidney Int. 1997. PMID: 9407519 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters